With prior knowledge that metformin may inhibit YAP nuclear translocation through the promotion AMPK-induced AMOT stabilization [149], we postulate that WBP2 can be used as a combinatorial therapy with metformin in HER2+ breast cancer [149]. Here, ERBB2 is linked to breast carcinoma.